Evaluation of antibody targeted controlled release nanoparticle systems

抗体靶向控释纳米颗粒系统的评估

• 批准号: G1001805/1
• 负责人: Christopher Scott
• 金额: $ 5.79万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1001805%2F1
• 关键词: Evaluation; antibody; targeted; controlled; release

The overarching objective of this proposal is the pilot evaluation of a novel antibody-drugdelivery technology, developed by the academic partner (Bioconjug Chem. 2008:19(8):1561-9; Pharm Res. 2008:25(1):135-46), using novel therapeutic antibodies that have beendeveloped by the industrial partner. Pursuance of this objective will provide the following:1. Development of the Research Fellow?s research expertise, management and leadership2. Development of new patent applications around the data produced3. Technical and commercial evaluation of a new therapeutic approach by the partners4. Development of a portfolio of data to facilitate future project grant application funding toagencies such as the MRCThis project builds on the established links between the industrial and academic partners.These groups have successfully collaborated in the past, producing joint IP, publications inquality journals (Clinical Cancer Research, Bioconjugate Chemistry and PlosONE), andultimately creating jobs and wealth in the local economy. A previous collaboration, focussedon the transfer of a protein engineering technology from the School of Pharmacy (through aKTP scheme; awarded A in final report; regional winner 2008), led to the development of anew bovine TB diagnostic kit by the company, which is currently undergoing evaluation in theUK and Ireland.In this current project, the academic partner has developed a novel nanoparticulate drugdelivery system and has already been provided with commercially insensitive antibodies totest as a proof of principle in vitro by the industrial partner. This project will build on thisbase, examining commercially prioritised antibodies (produced using the platformtechnologies underpinning the company) in relevant in vivo primary and metastatic tumourmodelsWe believe that this programme is an ideal mechanism to fund this pilot project, as it not onlyprovides the scope to undertake the project, but allows the Fellow to learn and champion thetechnology, thus developing their own CV, and provides a framework for further fundingopportunities from the MRC such as the DPFS

该提案的总体目标是对由学术合作伙伴开发的新型抗体药物递送技术（Bioconjug Chem. 2008:19(8):1561-9; Pharm Res. 2008:25(1):135-46）进行试点评估，该技术使用工业合作伙伴开发的新型治疗性抗体。实现这一目标将提供以下成果： 1．研究员的研究专业知识、管理和领导力的发展2。围绕所产生的数据开发新的专利申请3。合作伙伴对新治疗方法的技术和商业评估4。开发数据组合，以促进未来向 MRC 等机构申请资助。该项目建立在工业和学术合作伙伴之间已建立的联系的基础上。这些团体过去曾成功合作，生产联合知识产权，在高质量期刊（临床癌症研究、生物共轭化学和 PlosONE）上发表出版物，并最终为当地经济创造就业机会和财富。之前的合作重点是从药学院转让蛋白质工程技术（通过 aKTP 计划；在最终报告中获得 A 级；2008 年区域冠军），导致该公司开发了一种新的牛结核病诊断试剂盒，目前正在英国和爱尔兰进行评估。在当前的项目中，学术合作伙伴开发了一种新型纳米颗粒药物输送系统，并已提供商业上不敏感的产品 由工业合作伙伴进行抗体测试作为体外原理证明。该项目将在此基础上建立，在相关的体内原发性和转移性肿瘤模型中检查商业化优先抗体（使用支撑公司的平台技术生产）。我们相信，该计划是资助该试点项目的理想机制，因为它不仅提供了开展该项目的范围，而且允许研究员学习和支持该技术，从而开发自己的简历，并为 来自 MRC 的进一步资助机会，例如 DPFS